-+ 0.00%
-+ 0.00%
-+ 0.00%

Rodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12

Benzinga·07/07/2026 16:49:34
Listen to the news
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Price Target of $12.